Interaction Checker
Potential Interaction
Darunavir/cobicistat (DRV/c)
Emtricitabine/Tenofovir alafenamide for PrEP (FTC/TAF, PrEP)
Quality of Evidence: Very Low
Summary:
Emtricitabine and tenofovir alafenamide used as PrEP are not expected to be coadministered with antiretrovirals. Coadministration with emtricitabine/tenofovir alafenamide has not been studied. Coadministration with darunavir/cobicistat (800/150 mg once daily) and tenofovir alafenamide alone (25 mg once daily) increased tenofovir AUC and Cmax by 224% and 216%, respectively. No significant effects were observed on darunavir pharmacokinetics with either darunavir/ritonavir or darunavir/cobicistat. When administered with darunavir/cobicistat for the treatment of HIV, the recommended dose of Descovy is 200/10 mg once daily (where available).
Description:
View all available interactions with Darunavir/cobicistat (DRV/c) by clicking here.
Copyright © 2025 The University of Liverpool. All rights reserved.